Calidi Biotherapeutics, Inc.
CLDI· NYSE
CLDICalidi Biotherapeutics, Inc.
Filed May 15, 2023 · 10-Q · 45 days after period end · 0001193125-23-145095
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Net Income | -$6.46M | -$7.74M |
| EPS Diluted | -$0.75 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Calidi Biotherapeutics, Inc. · CIK 1855485 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end
